871 related articles for article (PubMed ID: 31134427)
21. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
22. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Guglin M; Krischer J; Tamura R; Fink A; Bello-Matricaria L; McCaskill-Stevens W; Munster PN
J Am Coll Cardiol; 2019 Jun; 73(22):2859-2868. PubMed ID: 31171092
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.
Słowik A; Jagielski P; Potocki P; Streb J; Ochenduszko S; Wysocki P; Gajos G; Konduracka E
Kardiol Pol; 2020 Feb; 78(2):131-137. PubMed ID: 31995035
[TBL] [Abstract][Full Text] [Related]
24. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.
Geisberg CA; Abdallah WM; da Silva M; Silverstein C; Smith HM; Abramson V; Mayer I; Means-Powell J; Freehardt D; White B; Lenihan D; Sawyer DB
J Card Fail; 2013 Jan; 19(1):10-5. PubMed ID: 23273589
[TBL] [Abstract][Full Text] [Related]
25. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
26. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
27. Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy.
Shah P; Garris R; Abboud R; Vasudev R; Patel H; Doshi R; Shamoon F; Bikkina M
Am J Cardiol; 2019 Sep; 124(5):789-794. PubMed ID: 31307662
[TBL] [Abstract][Full Text] [Related]
28. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
[TBL] [Abstract][Full Text] [Related]
29. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
30. Management of Heart Failure in Cancer Patients and Cancer Survivors.
Finet JE
Heart Fail Clin; 2017 Apr; 13(2):253-288. PubMed ID: 28279414
[TBL] [Abstract][Full Text] [Related]
31. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
32. Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer.
Umadat G; Ray J; Cornell L; Pillai D; Gharacholou SM
Am J Cardiol; 2023 Feb; 188():68-79. PubMed ID: 36473307
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
Levis BE; Binkley PF; Shapiro CL
Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
35. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
[TBL] [Abstract][Full Text] [Related]
36. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Chotenimitkhun R; D'Agostino R; Lawrence JA; Hamilton CA; Jordan JH; Vasu S; Lash TL; Yeboah J; Herrington DM; Hundley WG
Can J Cardiol; 2015 Mar; 31(3):302-7. PubMed ID: 25662284
[TBL] [Abstract][Full Text] [Related]
37. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
38. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
39. Excess heart age in young breast cancer survivors over 2-year follow-up.
Vo JB; Kenzik KM; Landier W; Raju D; Kirklin JK; Meneses K
Cancer Causes Control; 2021 Jun; 32(6):617-626. PubMed ID: 33763790
[TBL] [Abstract][Full Text] [Related]
40. Role of Speckle Tracking Echocardiography in the Evaluation of Breast Cancer Patients Undergoing Chemotherapy: Review and Meta-analysis of the Literature.
Bergamini C; Dolci G; Truong S; Zanolla L; Benfari G; Fiorio E; Rossi A; Ribichini FL
Cardiovasc Toxicol; 2019 Dec; 19(6):485-492. PubMed ID: 31049776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
